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Here we show that tyrosine phosphorylation of caveolin-2 (Cav-2) negatively regulates the anti-pro-
liferative function of transforming growth factor beta (TGF-beta) in endothelial cells. In contrast to
wild-type-Cav-2, retroviral re-expression of Y19/27F-Cav-2 in Cav-2 knockout endothelial cells did
not affect anti-proliferative effect of TGF-beta compared to empty vector. Conversely, although less
effective than wild-type, re-expression of S23/36A-Cav-2 reduced the effect of TGF-beta compared to
empty vector. This differential effect of tyrosine and serine phosphorylation mutants of Cav-2 cor-
related with TGF-beta-induced Smad3 phosphorylation and transcriptional activation of plasmino-
gen activator inhibitor-1. Thus tyrosine-phosphorylated Cav-2 counteracts anti-proliferative effect
of TGF-beta in endothelial cells.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Caveolins are key components of detergent resistant cholesterol
lipid rich membranes including lipid rafts and caveolae. Three
members were identiﬁed within the caveolin protein family: Cave-
olin-1 (Cav-1), Cav-2, and Cav-3. Cav-1 and -2 are ubiquitously co-
expressed, while Cav-3 is muscle speciﬁc [1–5]. Caveolins play
numerous important roles. In addition to being key structural pro-
teins that organize caveolae, caveolin proteins are important in
regulating endocytosis and various aspects of cellular signaling
[6] including endothelial cells [7]. Although relative to Cav-1, the
functional role of Cav-2 is less well deﬁned, recent studies have
started to present a growing body of evidence suggesting tissue/
cell speciﬁc role for Cav-2 [8]. For example, initial observations
involving Cav-2 knockout (KO) mice revealed hyperplasia in the
lung [9], suggesting a role for Cav-2 in regulating lung cell prolifer-
ation and/or differentiation.
Transforming growth factor-b (TGF-b) is a multifunctional di-
meric polypeptide growth factor capable of regulating prolifera-
tion, differentiation, migration, extracellular matrix production
and survival of various cell types. Cell responses to TGF-b are med-
iated through speciﬁc transmembrane type I and type II Ser/Thr ki-
nase receptors [10,11]. The signaling pathway is initiated by TGF-bchemical Societies. Published by E
wa).binding to the TGF-b type II receptor (TbR-II). Upon ligand binding,
TbR-II recruits and phosphorylates TbR-I, also known as activin
receptor-like kinase (Alk), which transduces the signal to the nu-
cleus through members of the Smad family [12,13]. Most cell types
express a form of TbR-I known as Alk5. ECs also co-express an addi-
tional TbR-I known as Alk1. Activated Alk5 induces the phosphor-
ylation of Smad2 and Smad3 and activation of Alk5/Smad2/3
pathway leads to inhibition of cell proliferation and is associated
with a mature endothelium with increased expression of genes
such as plasminogen activator inhibitor-1 (PAI-1), collagen type I
(Col-1).
Recently, we have determined that Cav-2 is the negative regu-
lator of anti-proliferative effect of TGF-b/Alk-5/Smad2/3 pathway
in ECs [14]. The purpose of the present study is to investigate the
molecular mechanisms of Cav-2-dependent inhibition of TGF-b/
Alk5 pathway in ECs. Speciﬁcally, we have examined the relative
contribution of N-terminal serine and tyrosine phosphorylation
of Cav-2 in regulating anti-proliferative function of TGF-b/Alk5/
Smad3/PAI-1 pathway in ECs. Our data indicates that tyrosine
but not serine phosphorylation is essential for the negative regula-
tion of anti-proliferative function and signaling of TGF-b in ECs.
2. Materials and methods
The detailed Materials and methods can be found in Supple-
mentary Data.lsevier B.V. All rights reserved.
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Antibodies against total Cav-2, PY27-Cav-2, Cav-1 and Hsp-90
were from BD Transduction Labs; Antibodies to phospho-Smad3
and Lamin A/C were from Cell Signaling Biotech; Antibody to phos-
pho-histone 3 was from Santa Cruz Biotech; Antibodies to PAI-1
and PY19-Cav-2 were from Abcam.
2.2. Endothelial cells (MLECs)
Mouse lung endothelial cells (MLECs) were isolated from 2 to 3-
week-old wild type (WT) and Cav-2 KO mice as originally de-
scribed [15] (For details see Supplementary Data). Human lung
microvascular endothelial cells (HULECs) were obtained from the
Centers for Disease Control and Prevention.
2.3. Retroviral re-expression of WT as well as serine and tyrosine
phosphorylation-deﬁcient mutants of Cav-2 in Cav-2 KO MLECs
Cav-2 KO MLECs stably expressing empty vector pBABE-puro or
pBABE-puro plus WT-Cav-2, S23/36A-Cav-2, and Y19/27F-Cav-2
were generated as previously described [14] (For details see Sup-
plementary Data).
2.4. MTT colorimetric proliferation assay
MLECs were seeded onto 24-well plates at 4  103/well in com-
plete medium. Next day, medium was replaced with fresh medium
without or with human TGF-b1 (Peprotech). After 6 h (day 0) or
5 days of incubation in the absence or presence of TGF-b (1 ng/
ml), MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide; Sigma) stock solution was added and the samples were
processed and measured as described in Supplementary Data.
2.5. Cell counts based proliferation assay
MLECs were plated onto six well plates at 104 cells per well for
24 h, followed by a medium change and further incubation in com-
plete medium in the absence or presence of TGF-b for 6 days. At the
end of the experiment, cells were trypsinized and viable cells
counted with an automatic cell counter Countess (Invitrogen cor-
poration). Cell number was expressed as mean ± S.D. (n = 3) from
one representative out of a total three experiments.
2.6. Immunoﬂuorescence microscopy
Cells were ﬁxed with 3% paraformaldehyde in Dulbecco’s phos-
phate-buffered saline, pH 7.4 (DPBS), for 30 min, and washed three
times with DPBS. Cells were then incubated sequentially with 0.1%
Triton X-100 (v/v) in DPBS for 10 min, DPBS plus 5% goat serum for
30 min, and thereafter with anti-Cav-2 antibody (1:100) in 0.2%
BSA for 2 h, washed three times, and incubated with Alexa Fluor
488 nm-labeled secondary antibody (Invitrogen Corp.) diluted
1:500, followed by staining with DAPI (Sigma). Slides were
mounted with Slowfade (Molecular Probes, Inc., Eugene, OR), and
cells were observed and images captured with 20 objective using
an Olympus IX70 epiﬂuorescence microscope.
2.7. Immunoblotting
Cells were lysed in Laemmli SDS loading buffer, followed by
boiling for 5 min. An equal protein amount was loaded on SDS–
PAGE, and proteins were electro-transferred onto nitrocellulose
membranes. The membranes were washed in Tris-buffered saline
with 0.1% Tween, blocked in 5% milk, and incubated with the
appropriate primary antibodies diluted 1:1000–1:20000 at 4 C
overnight, followed by incubation with horseradish peroxidase la-beled secondary antibodies diluted 1:10000, and developed by en-
hanced chemiluminescence.
2.8. Triton-100 insolubility assay
MLECs were lysed with 0.1% Triton X-100 in MBS (pH 6.5), ly-
sates were incubated for 10 min on ice, and centrifuged at
48000g at 4 C for 30 min. The supernatant was collected and
considered as Triton X-100 soluble fraction (+), while the Triton
X-100 insoluble () pellet was solubilized with an equal volume
of SDS–PAGE loading buffer, equal volumes of both samples were
loaded on SDS–PAGE gel and immunoblotted. % Distribution for
each detected protein in TX-100 soluble versus insoluble fraction
was calculated based on the densitometric values obtained using
Image J (NIH) and expressed as Mean ± S.D. (n = 3).
2.9. Nuclear/Cytosol fractionation
The nuclear and cytosolic fractions were isolated using the Nu-
clear/Cytosol Extraction Kit (BioVision) according to the manufac-
turer’s protocol, followed by standard immunoblotting of nuclear
and cytosolic fractions. In addition, the densitometric ratios of p-
Smad3/Lamin A/C were assessed for nuclear fractions using Image
J (NIH) and expressed as Mean ± S.D. (n = 3).
2.10. RNA isolation and quantiﬁcation of speciﬁc gene expression by
real-time PCR
Total RNA isolation and RT-PCR of control and TGF-b-treated
MLECs were performed as previously described [14] (For details
see Supplementary Data).
3. Results
3.1. Expression levels and subcellular targeting of retrovirally re-
expressed serine and tyrosine phosphorylation-deﬁcient mutants are
comparable to WT Cav-2
Previously, we have determined that Cav-2 KOMLECsweremore
sensitive than WT MLECs to anti-proliferative effect of TGF-b and
that retroviral re-expression of WT Cav-2 in Cav-2 KO MLECs re-
sulted in a similar response to TGF-b as inWTMLECs [14]. However,
the detailed molecular mechanisms of this inhibitory role of Cav-2
in anti-proliferative effect of TGF-b in ECs have not been examined.
Because Cav-2 has been previously shown to be phosphorylated at
serine residues 23 and 36 [16,17] as well as tyrosine residues 19
[18] and 27 [19], in the current study we have examined the role
of N-terminal serine and tyrosine phosphorylation of Cav-2 in
negating the anti-proliferative effect and signaling of TGF-b in ECs.
Speciﬁcally, we have re-expressed WT-Cav-2, serine residues 23
and 36 phosphorylation-deﬁcient mutant (S23/36A-Cav-2) as well
as tyrosine residues 19 and 27 phosphorylation-deﬁcient mutant
(Y19/27F-Cav-2) in Cav-2 KO MLECs. Using standard immunoblot-
ting technique we have determined comparable expression levels
of Cav-2 in Cav-2 KO MLECs re-expressing WT-Cav-2 as well as
S23/36A-Cav-2 and Y19/27F (For details see Supplementary Results
and Fig. S1A). Next, using immunoﬂuorescence labeling with Cav-2
antibody, we have also determined that similar toWT-Cav-2, the re-
expressed S23/36A-Cav-2 and Y19/27F-Cav-2 targeted to perinu-
clear and plasmamembrane regions (For details see Supplementary
Results and Fig. S1B). Finally, using TX-100 insolubility assay, we
have also determined that just as retrovirally-expressed WT-Cav-
2, both S23/36A-Cav-2 and Y19/27F-Cav-2 were TX-100-insoluble
and co-fractionated with Cav-1 and ﬂotillin-1 (Flo-1), protein
markers of caveolae and lipid rafts, respectively but not with the
cytosolic marker, Hsp-90 (For details see Supplementary Results
and Fig. S2).
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phosphorylation of Cav-2 in negating anti-proliferative effect of TGF-b
in MLECs
Here, we have used previously (Fig. S1) characterized pBABE,
WT-Cav-2, S23/36A-Cav-2 andY19/27F-Cav-2MLECs andcompared
the inhibitory effect of TGF-b on proliferation using the two inde-
pendentproliferationassays: cell count andMTTaswell as immuno-
blotting with anti-phospho-histone 3 (mitotic marker) antibody.
In a cell count proliferation assay (Fig. 1A) treatment with TGF-b
(1 ng/ml) reduced cell number by c.a. 52.4 ± 3.8% in pBABE cells
and this inhibitory effect of TGF-b was reduced to 5.5 ± 3% by re-
expression of WT-Cav-2. Re-expression of S23/36A-Cav-2 still re-
duced the inhibitory effect of TGF-b to 15.2 ± 5.8%. In contrast to
S23/36A, re-expression of Y19/27F-Cav-2 only marginally reduced
inhibitory effect of TGF-b to 45.2 ± 4.8%.
In an MTT proliferation assay (Fig. 1B), treatment with TGF-b re-
duced OD values by 45.1 ± 5.7% in pBABE and re-expression of WT-
Cav-2 completely reversed this inhibition. Re-expression of S23/
36A-Cav-2 still reduced the inhibitory effect of TGF-b to
24.0 ± 1.1%, In contrast to S23/36A-Cav-2, re-expression of Y19/
27F-Cav-2 did not affect the inhibitory effect of TGF-b (45 ± 4.9%)
compared to pBABE.
Similar to cell count and MTT proliferation assays, TGF-b also
reduced the relative levels of histone H3 phosphorylation by
49.5 ± 11.9% in pBABE and re-expression of WT-Cav-2 completely
reversed the inhibitory effect of TGF-b (Fig. 1C). Re-expression of
S23/36A-Cav-2 still reduced the inhibitory effect of TGF-b to
19.2 ± 3.9%, while re-expression of Y19/27F-Cav-2 had only mar-
ginal effect (c.a. 40.0 ± 6.3% inhibition by TGF-b). Taken together,
the data obtained with the two independent proliferation assays
and immunoblotting with anti-mitotic marker antibody suggest
that N-terminal tyrosine phosphorylation of Cav-2 plays a critical
role in inhibiting anti-proliferative effect of TGF-b in ECs. In addi-
tion, N-terminal serine phosphorylation is only modestly involved
in negating anti-proliferative effect of TGF-b by Cav-2.Fig. 1. Effect of TGF-b on proliferation of Cav-2 KO MLECs re-expressing WT and
phosphorylation-deﬁcient mutants of Cav-2. (A) Effect of TGF-b on MLECs prolif-
eration determined by cell count. pBABE, WT-Cav-2, S23/36A-Cav-2, and Y19/27F-
Cav-2 MLECs were plated at 104 cells per well of six well plates and 24 h later
incubated without or with TGF-b (1 ng/ml) for 5 days. Cell numbers were
determined using Cell Countess and expressed as Mean ± S.D. of replicate samples
(n = 3) from one representative out of a total three experiments. (B) Effect of TGF-b
on MLECs proliferation determined by MTT proliferation assay. pBABE, WT-Cav-2,
S23/36A-Cav-2, and Y19/27F-Cav-2 MLECs were plated at 2  103 cells per well of
24 well plates and 24 h later incubated without or with TGF-b (1 ng/ml) for 5 days,
followed by processing for MTT proliferation assay. Optical density (OD) was
measured using a plate reader with a test wavelength of 570 nm and a reference
wavelength of 750 nm (570–750 nm) to obtain a sample signal, and expressed as
Mean ± S.D. of replicate samples (n = 3). Values are from one representative out of a
total four experiments. (C) Effect of TGF-b on MLECs proliferation determined by
immunoblotting with anti-mitotic marker protein, phospho-histone H3 (P-Histone
H3) antibody. WT-Cav-2, S23/36A-Cav-2, and Y19/27F-Cav-2 MLECs were plated at
3  105 cells onto 150 mm dishes, 24 h later incubated without or with TGF-b
(1 ng/ml) for additional 48 h, lysed and processed for SDS–PAGE and immunoblot-
ting with indicated antibodies as described in Section 2. Bottom graph: Densito-
metric ratios of P-Histone H3/Hsp-90 from control (blank bars) and treated with
TGF-b (solid bars) samples quantiﬁed based on the above immunoblots and
expressed as Means ± S.D. (n = 3).3.3. N-terminal tyrosine phosphorylation is more critical than serine
phosphorylation of Cav-2 in negating TGF-b-stimulated Smad3
phosphorylation in MLECs
Smad3 is a key downstream mediator of TGF-b-induced anti-
proliferative effect in various cell types, including ECs. Thus we
have examined the role of N-terminal phosphorylation of Cav-2
in inhibiting TGF-b-stimulated Smad3 phosphorylation in MLECs.
Upon stimulation with TGF-b, Smad3 is phosphorylated by Alk5
and translocates to the nucleus. To conﬁrm that the same is true
for MLECs, we isolated nuclear and cytosolic fractions from control
and treated with TGF-b (1 ng/ml; 1 h) pBABE, WT-Cav-2, S23/36A-
Cav-2 as well as Y19/27F-Cav-2 MLECs and determined the levels
of Smad3 phosphorylation by immunoblotting with P-Smad3-spe-
ciﬁc antibody. As seen in Fig. 2A, the P-Smad3-speciﬁc signal was
enriched in nuclear (N) but not cytosolic (C) fractions. Therefore,
we have further determined the ratios of P-Smad3/Lamin A/C (nu-
clear membrane marker protein) in nuclear fractions (Fig. 2B and
C). Treatment with TGF-b increased the P-Smad3/Lamin A/C ratio
by c.a. twofold in pBABE MLECs, while re-expression of
WT-Cav-2 blocked this increase by TGF-b. Re-expression of S23/
36A-Cav-2 reduced the stimulating effect of TGF-b to only c.a.
1.14-fold. In contrast to S23/36A-Cav-2, re-expression of Y19/
27F-Cav-2 did not reduce TGF-b-induced increase in Smad3 phos-
phorylation compared to pBABE MLECs. These data suggest that N-
terminal tyrosine phosphorylation is essential molecular event
allowing Cav-2 to inhibit TGF-b-induced stimulation of Smad3
phosphorylation.
Fig. 2. Effect of TGF-b on Smad3 phosphorylation in Cav-2 KO MLECs re-expressing WT and phosphorylation-deﬁcient mutants of Cav-2. WT-Cav-2, S23/36A-Cav-2, and Y19/
27F-Cav-2 MLECs were plated at 5  105 cells onto 60 mm dishes, 24 h later incubated without or with TGF-b (1 ng/ml) for 1 h, followed by cytosol (C) and nuclear (N)
fractionation (Biovision). Both C and N fractions were then processed for SDS–PAGE and immunoblotting with indicated antibodies. Top graph: Densitometric ratios of
phospho-Smad3 (P-Smad3)/Lamin A/C (nuclear protein marker) in N fractions from control (blank bars) and treated with TGF-b (solid bars) samples quantiﬁed based on the
above immunoblots and expressed as Means ± S.D. (n = 3). Bottom graph: Fold-change by TGF-b relative to respective control samples, quantiﬁed based on N fraction and
expressed as Means ± S.D. (n = 3).
3320 B. Abel et al. / FEBS Letters 586 (2012) 3317–33233.4. N-terminal tyrosine phosphorylation is more critical than serine
phosphorylation of Cav-2 in negating TGF-b-stimulated PAI-1 and Col-
1 gene expression in MLECs
To gain further insights into how serine and tyrosine deﬁcient
mutants affect TGF-b/Alk5/Smad3 pathway downstream of Smad3,
we have performed RT-PCR to determine mRNA levels of the two
target genes of Smad3, namely PAI-1 and Col-1 in control and trea-
ted with TGF-b (1 ng/ml; 48 h) pBABE, WT-Cav-2, S23/36A-Cav-2,
and Y19/27F-Cav-2 MLECs.
As seen in Fig. 3A, treatment with TGF-b increased PAI-1 mRNA
expression by c.a. 10.1-fold in pBABE MLECs, while re-expression
of WT-Cav-2 reduced this increase by TGF-b to c.a. 2.9-fold. Re-
expression of S23/36A-Cav-2 still reduced the stimulating effect
of TGF-b to c.a. 3.9-fold. In contrast to S23/36A-Cav-2, re-expres-
sion of Y19/27F-Cav-2 failed to reduce TGF-b-induced increase in
PAI-1 gene expression compared to pBABE. These data suggest that
N-terminal tyrosine phosphorylation of Cav-2 plays a key role in
diminishing TGF-b-induced PAI-1 gene expression in MLECs, while
serine phosphorylation is of marginal importance.Next, we have also examined the role of Cav-2 phosphorylation
in TGF-b-stimulated Col-1 gene expression. As seen in Fig. 3B,
treatment with TGF-b increased Col-1 mRNA expression by c.a.
45.7-fold in pBABE MLECs, while re-expression of WT-Cav-2 re-
duced this increase by TGF-b to only c.a. 2.6-fold. Re-expression
of S23/36A-Cav-2 still reduced the stimulating effect of TGF-b to
c.a. 21.9-fold. Re-expression of Y19/27F-Cav-2 only marginally re-
duced increase in Col-1 mRNA level by TGF-b to 34.1-fold. These
data suggest that N-terminal tyrosine phosphorylation of Cav-2 is
more critical than serine phosphorylation of Cav-2 in reducing
TGF-b-induced Col-1 gene expression in MLECs.
3.5. N-terminal tyrosine phosphorylation is more critical than serine
phosphorylation of Cav-2 in suppressing TGF-b-stimulated PAI-1
protein expression in MLECs
To further conﬁrm if N-terminal tyrosine phosphorylation of
Cav-2 in addition to PAI-1 and Col-1 transcript expression levels
also inhibits TGF-b-induced PAI-1 and Col-1 protein expression
levels, we have performed immunoblotting with anti-PAI-1 and
Fig. 4. Effect of TGF-b on PAI-1 protein expression in Cav-2 KO MLECs re-expressing
WT and phosphorylation-deﬁcient mutants of Cav-2. WT-Cav-2, S23/36A-Cav-2,
and Y19/27F-Cav-2 MLECs were plated at 3  105 cells onto 150 mm dishes, 24 h
later incubated without or with TGF-b (1 ng/ml) for additional 48 h, lysed and
processed for SDS–PAGE and immunoblotting with indicated antibodies as
described in Section 2. Top graph: Densitometric ratios of PAI-1/Hsp-90 from
control (blank bars) and treated with TGF-b (solid bars) samples quantiﬁed based
on the above immunoblots and expressed as Means ± S.D. (n = 3). Bottom graph:
Fold-change by TGF-b relative to respective control samples expressed as
Means ± S.D. (n = 3).
Fig. 3. Effect of TGF-b on PAI-1 and Col 1 gene expression in Cav-2 KO MLECs re-
expressing WT and phosphorylation-deﬁcient mutants of Cav-2. WT-Cav-2, S23/
36A-Cav-2, and Y19/27F-Cav-2 MLECs were plated at 3  105 per 150 mm dish for
24 h, incubated without or with TGF-b (1 ng/ml) for additional 48 h, followed by
total RNA isolation and real-time PCR as described in Section 2. Data are expressed
as fold change by TGF-b relative to control samples, calculated based on the relative
amount of target mRNA normalized to the endogenous reference GAPDHmRNA and
represented as Mean ± S.D of three replications done in duplicates.
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(1 ng/ml; 72 h) increased PAI-1 protein expression level by c.a.
5.3-fold in pBABE MLECs, while re-expression of WT-Cav-2
reduced this increase by TGF-b to c.a. 1.7-fold. Similar to WT-
Cav-2, re-expression of S23/36A-Cav-2 still reduced the stimulat-
ing effect of TGF-b to c.a. 2.4-fold. In contrast to S23/36A-Cav-2,
re-expression of Y19/27F-Cav-2 did not reduce TGF-b-induced in-
crease in PAI-1 protein expression level compared to pBABE. These
data suggest that N-terminal tyrosine phosphorylation of Cav-2
plays a key role in suppressing TGF-b-induced PAI-1 protein
expression levels in MLECs, while serine phosphorylation is of mar-
ginal importance. We have also tried to determine if N-terminal
phosphorylation of Cav-2 affects Col-1 protein expression levels
by immunoblotting with the two independent Col-1-speciﬁc anti-
bodies (Millipore and Santa Cruz Biotech) but were unable to
detect speciﬁc signal (data not shown).
3.6. N-terminal tyrosine phosphorylation of Cav-2 is stimulated by
inhibition of tyrosine phosphatases in mouse and human ECs and
suppressed by pharmacological inhibition of Src and Abl kinases in
human ECs
Because of newly described here functional signiﬁcance of tyro-
sine phosphorylation in regulating TGF-b signaling and function in
ECs, next we have examined if tyrosine 19 and/or 27 phosphoryla-
tion of Cav-2 is regulated in ECs. Speciﬁcally, we have treated WT
MLECs with vascular endothelial growth factor (VEGF; 100 ng/ml),
H2O2 (0.5 mM), and sodium pervanadate (PV; 50 lM) for 30 min
and analyzed phosphorylation of Cav-2 using tyrosine 19 (PY19-
Cav-2) and tyrosine 27 (PY27-Cav-2) speciﬁc antibodies. As seen
in Fig. 5A, treatment with PV yielded an obvious increase inPY19-Cav-2 within the examined time frame. Unlike PY19-Cav-2,
no increase in PY27-Cav-2 was observed in PV-treated MLECs, pre-
sumably due to lack of speciﬁcity of PY27-Cav-2 antibody to mouse
Cav-2. Thus next we have examined potential regulation of tyro-
sine phosphorylation of Cav-2 in human lung microvascular ECs
(HULECs). Speciﬁcally, we have conﬁrmed that just as in MLECs,
PV treatment also resulted in stimulation of PY19-Cav-2 (Fig. 5B;
top immunoblot; lane #2 vs. #1 and Fig. 5C). In contrast to MLECs,
we have also demonstrated speciﬁc increase in PY27-Cav-2 by PV
(Fig. 5B; 2nd immunoblot from the top; lane #2 vs. #1 and
Fig. 5D). We have also tested a possible regulation of tyrosine phos-
phorylation of Cav-2 by TGF-b. 24 h pre-treatment with TGF-b had
only a modest inhibitory effect on PV-stimulated PY19-Cav-2 and
PY27-Cav-2 (lane # 3 vs. #2). In contrast, pre-treatment with Src
inhibitor, PP2 resulted in ca. 6.8-fold and 6.6-fold reduction of
PY19-Cav-2/Cav-2 and PY27-Cav-2/Cav-2 densitometric ratios,
respectively. Moreover, pre-treatment with Abl inhibitor, imatinib
resulted in ca. 2.3-fold reduction of both PY19-Cav-2 and PY27-
Cav-2. Our data suggest that N-terminal tyrosine phosphorylation
Fig. 5. Effect of selected pathophysiological activators and tyrosine kinase inhibitors on phosphorylation of Cav-2 at tyrosine residues 19 and 27. (A) MLECs were treated
without (control) or with VEGF (100 ng/ml), H2O2 (0.5 mM), or sodium pervanadate (PV; 50 lM) for 30 min, followed by lysis and immunoblotting with indicated antibodies.
(B) Human lung microvascular endothelial cells (HULECs) were treated without (control; lane #1) or with PV (lane #2) for 30 min, followed by lysis and immunoblotting with
indicated antibodies. In addition, cells were also pretreated before PV with 1 ng/ml of TGF-b for 24 h (PV + TGF-b; lane #3); 100 lM of Src family kinase inhibitor, PP2 for
30 min (PV + PP2; lane #4); and 20 lM of Abl kinase inhibitor, imatinib (PV + IM; lane #5). (C) Graphical representation of densitometric ratio of PY19-Cav-2/Cav-2 quantiﬁed
based on immunoblot in B and expressed as Means ± S.D. (n = 3). (D) Graphical representation of densitometric ratio of PY27-Cav-2/Cav-2 quantiﬁed based on immunoblot in
B and expressed as Means ± S.D. (n = 3).
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mouse and human ECs and may be mediated by Src family kinase
and possibly by Abl kinase in human ECs.
4. Discussion
Here by re-expressing WT and mutated forms of Cav-2 in Cav-2
KO MLECs, we have evaluated the relative contribution of N-termi-
nal serine and tyrosine phosphorylation sites to the inhibitory role
of Cav-2 in preventing the anti-proliferative function and signaling
of TGF-b in ECs. Speciﬁcally, we show that N-terminal tyrosine
phosphorylation of Cav-2 plays a critical role in inhibiting anti-pro-
liferative effect of TGF-b in ECs. In contrast to tyrosine, serine phos-
phorylation is only modestly involved in negating anti-proliferative
effect of TGF-b by Cav-2. Although Cav-2 has previously been
shown to be phosphorylated at N-terminal tyrosine residues 19
and 27 [18,19] and serine residues 23 and 36 [16,17], to our best
knowledge, no concurrent and comparative analysis of the relative
contribution of tyrosine and serine phosphorylation of Cav-2 to any
functional effect of Cav-2 has been reported to date. Thus the cur-
rent study is the ﬁrst one to simultaneously examine the involve-
ment of both N-terminal tyrosine and serine phosphorylation of
Cav-2 in regulating any cell function. In addition, in the present
study we provide ﬁrst evidence suggesting that tyrosine 19 and
27 phosphorylation of Cav-2may bemediated by Src family kinases
and that Abl kinase could possibly contribute to this process in
human ECs. Given the signiﬁcance of Src family kinases in numer-
ous EC speciﬁc processes, further studies examining if tyrosine
phosphorylation of Cav-2 could affect these processes in ECs are
clearly warranted.
The full dependence of anti- TGF-b-induced function and signal-
ing of Cav-2 on N-terminal tyrosine phosphorylation and only par-
tial dependence on N-terminal serine phosphorylation of Cav-2
could be observed using the two independent proliferation assays:
cell count and MTT, and correlated with the respective effect on the
levels of a mitotic marker protein, phospho-histone H3 in MLECs.We have recently reported that SB-505124, a compound which
inhibits Alk5 without affecting Alk1 [20], blocked anti-proliferative
effect of TGF-b on Cav-2 KO MLECs as well as Smad2 hyper-activa-
tion [14]. This data suggests that Alk5/Smad2/3 pathway is respon-
sible for anti-proliferative effect of TGF-b in MLECs, consistent with
previous reports in other ECs [21,22]. Importantly, in the current
study, we show that N-terminal tyrosine phosphorylation of Cav-
2 is essential for the inhibitory effect of Cav-2 on TGF-b-induced
stimulation of Smad3 phosphorylation. Moreover, by analyzing
the transcriptional activation of the two known transcription
target genes of phosphorylated Smad2/3, we show that tyrosine
phosphorylation is more critical than serine phosphorylation for
the suppressive effect of Cav-2 on PAI-1 and to a lesser extent
Col-1 gene induction by TGF-b. In particular, the inability of tyro-
sine phosphorylation-deﬁcient mutant of Cav-2 to suppress TGF-
b-induced PAI-1 mRNA and protein expression levels correlates
well with the data obtained using proliferation assays. Interest-
ingly, PAI-1 has previously been shown to be a speciﬁc target of
Alk5 which was implicated in inhibiting EC proliferation [22]. Thus,
it is possible that tyrosine phosphorylation of Cav-2 inhibits
anti-proliferative effect of TGF-b, at least partially via suppressing
PAI-1 transcriptional activation and subsequent protein expression.
What is the mechanism via which tyrosine phosphorylation of
Cav-2 regulates TGF-b function and signaling in ECs? Based on
the fact that speciﬁc inhibitor of Alk5 reversed the hyper-inhibi-
tory effect of TGF-b on Cav-2 KOMLECs [14] and that re-expression
of WT Cav-2 inhibits Smad3 phosphorylation, the direct interaction
between tyrosine phosphorylated Cav-2 and Alk5 seems to be
plausible. However, we were unable to detect direct interactions
between Cav-2 and Alk5 in MLEC or primary human EC lysates
by co-immunoprecipitation, presumably due to low expression
levels of Alk5 in examined ECs (not shown). In addition to direct
interaction, we have previously examined the possibility that
Cav-2 could modify Alk5 or TGRII as well as Smad2/3 targeting
to caveolar/lipid raft domains. However, we could not see any sig-
niﬁcant differences in caveolar/lipid raft targeting of previously
B. Abel et al. / FEBS Letters 586 (2012) 3317–3323 3323mentioned protein components of the TGF-b signaling pathway
[14]. Alternatively, tyrosine-phosphorylated Cav-2 could possibly
affect the anti-proliferative signaling and function of TGF-b in
ECs indirectly, perhaps via interacting with one or more of Src
homology 2 domain (SH2) domain containing proteins which in
turn could suppress Alk5/Smad2/3 pathway. Of note, tyrosine
phosphorylation-dependent interaction of Cav-2 with such SH2
domain containing proteins as c-Src, Nck, or Ras-GAP was previ-
ously reported using Gst-fused Cav-2 approach and c-Src-over-
expressing 3T3 cells [18,19].
In summary, our data indicate that N-terminal tyrosine phos-
phorylated Cav-2 negatively regulates anti-proliferative function
and Alk5/Smad3-dependent signaling of TGF-b in MLECs, while
N-terminal serine phosphorylation plays only a minor role.
Further studies elucidating the detailed mechanisms responsi-
ble for inhibitory regulation of TGF-b-induced signaling and func-
tion in ECs by tyrosine-phosphorylated Cav-2 will be necessary.
In particular, investigation into the speciﬁc contribution of tyrosine
19 versus 27, identifying possibly different interacting protein
partner(s) for WT Cav-2 versus tyrosine phosphorylation-deﬁcient
mutant(s) of Cav-2 might provide further mechanistic insights into
the observed inhibitory effect of tyrosine phosphorylated Cav-2 on
anti-proliferative signaling and function of TGF-b.
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